Skip to main content

Advertisement

Table 1 MTS transition schedule and final dosages by ADHD medication at baseline

From: Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Baseline ADHD Medication Baseline Dose, mg/d Converted MTS Dose, mg/9 hour Final MTS Dose Subjects, n (%)
    10 mg (n = 23) 15 mg (n = 30) 20 mg (n = 52) 30 mg (n = 59)
Concerta® (n = 112) 18 (n = 13) 10 5 (38.5) 5 (38.5) 3 (23.1) 0
  27 (n = 24) 15 1 (4.2) 9 (37.5) 10 (41.7) 4 (16.7)
  36 (n = 46) 20 0 1 (2.2) 26 (56.5) 19 (41.3)
  45 (n = 2) 20 0 0 1 (50.0) 1 (50.0)
  54 (n = 27) 30 0 0 1 (3.7) 26 (96.3)
Ritalin LA® (n = 26) 10 (n = 3) 10 2 (66.7) 1 (33.3) 0 0
  20 (n = 9) 10 4 (44.4) 3 (33.3) 2 (22.2) 0
  30 (n = 9) 15 0 3 (33.3) 5 (55.6) 1 (11.1)
  40 (n = 2) 20 0 1 (50.0) 0 1 (50.0)
  50 (n = 3) 30 0 0 0 3 (100.0)
Metadate CD® (n = 26) 10 (n = 1) 10 1 (100.0) 0 0 0
  15 (n = 1) 10 1 (100.0) 0 0 0
  20 (n = 12) 10 8 (66.7) 4 (33.3) 0 0
  30 (n = 7) 15 1 (14.3) 3 (42.9) 1 (14.3) 2 (28.6)
  40 (n = 3) 20 0 0 2 (66.7) 1 (33.3)
  50 (n = 2) 30 0 0 1 (50.0) 1 (50.0)
  1. MTS = methylphenidate transdermal system; ADHD = attention-deficit/hyperactivity disorder.